Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance

References

• Li J, Wang F, Sun D, Wang R. A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours. J Drug Target. 2016;24(7):590–602. doi:10.3109/1061186X.2016.115456126878228
   PubMed Web of Science ®Google Scholar
• Podolski-Renić A, Banković J, Dinić J, et al. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. Eur J Pharm Sci. 2017;105:159–168. doi:10.1016/j.ejps.2017.05.01128502672
   PubMed Web of Science ®Google Scholar
• Liu W, Lo YL, Hsu C, et al. CS-PEI/Beclin-siRNA downregulate multidrug resistance proteins and increase paclitaxel therapeutic efficacy against NSCLC. Mol Ther Nucleic Acids. 2019;17:477–490. doi:10.1016/j.omtn.2019.06.01731336235
   PubMedGoogle Scholar
• Jandial DD, Krill LS, Chen L, et al. Induction of G2M arrest by flavokawain A, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin. Molecules. 2017;22(3):pii: E462. doi:10.3390/molecules22030462
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zvi YS, Batko B, et al. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Sci Rep. 2018;8(1):14294–14306. doi:10.1038/s41598-018-32428-930250282
   PubMedGoogle Scholar
• Li J, Zheng L, Yan M, et al. Activity and mechanism of flavokawain A in inhibiting P-glycoprotein expression in paclitaxel resistance of lung cancer. Oncol Lett. 2020;19(1):379–387. doi:10.3892/ol.2019.1106931897150
   PubMed Web of Science ®Google Scholar
• Yao Y, Wang T, Liu Y, Zhang N. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):1374–1383. doi:10.1080/21691401.2019.159694330977418
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu Y, Kim YJ, Mac J, Zhuang R, Wang P. Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment. RSC Adv. 2017;7(32):19685–19693. doi:10.1039/c7ra01100h28603607
   PubMed Web of Science ®Google Scholar
• Yang C, Pang X, Chen W, et al. Environmentally responsive dual-targeting nanotheranostics for overcoming cancer multidrug resistance. Sci Bull (Beijing). 2019;64:705–714. doi:doi.10.1016/j.scib.2019.04.019
   PubMed Web of Science ®Google Scholar
• Zhao C, Shao L, Lu J, Deng X, Tong Y, Wu Y. Hybrid prodrug nanoparticles with tumor penetration and programmed drug activation for enhanced chemoresistant cancer therapy. ACS Appl Mater Interfaces. 2017;9(22):18450–18461. doi:10.1021/acsami.7b0190828513140
   PubMed Web of Science ®Google Scholar
• Lan Y, Sun Y, Yang T, et al. Co-delivery of paclitaxel by a capsaicin prodrug micelle facilitating for combination therapy on breast cancer. Mol Pharm. 2019;16(8):3430–3440. doi:10.1021/acs.molpharmaceut.9b0020931199661
   PubMedGoogle Scholar
• Meng H, Wang M, Liu H, et al. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015;9(4):3540–3557. doi:10.1021/acsnano.5b0051025776964
   PubMed Web of Science ®Google Scholar
• Zhao MD, Li JQ, Chen FY, et al. Co-delivery of curcumin and paclitaxel by “Core-Shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer. Int J Nanomedicine. 2019;14:9453–9467. doi:10.2147/IJN.S22457931819443
   PubMed Web of Science ®Google Scholar
• Zhang W, Shen J, Su H, et al. Co-delivery of cisplatin prodrug and chlorin e6 by mesoporous silica nanoparticles for chemo-photodynamic combination therapy to combat drug resistance. ACS Appl Mater Interfaces. 2016;8(21):13332–13340. doi:10.1021/acsami.6b0388127164222
   PubMed Web of Science ®Google Scholar
• Fan L, Jin B, Zhang S, Song C, Li Q. Stimuli-free programmable drug release for combination chemo-therapy. Nanoscale. 2016;8(25):12553–12559. doi:10.1039/c5nr06305a26554664
   PubMed Web of Science ®Google Scholar
• Castillo RR, Colilla M, Vallet-Regi M. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv. 2017;14(2):229–243. doi:10.1080/17425247.2016.121163727402029
   PubMed Web of Science ®Google Scholar
• Sheu M-T, Jhan H-J, Su C-Y, et al. Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. Colloids Surf B Biointerfaces. 2016;143:260–270. doi:10.1016/j.colsurfb.2016.03.05427022865
   PubMed Web of Science ®Google Scholar
• Ganguly K, Chaturvedi K, More UA, Nadagouda MN, Aminabhavi TM. Polysaccharide-based micro/nanohydrogels for delivering macromolecular therapeutics. J Control Release. 2014;193:162–173. doi:10.1016/j.jconrel.2014.05.01424845128
   PubMed Web of Science ®Google Scholar
• Liao L, Liu J, Dreaden EC, et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc. 2014;136(16):5896–5899. doi:10.1021/ja502011g24724706
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang T, Yang S, et al. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J Control Release. 2016;238:10–21. doi:10.1016/j.jconrel.2016.07.02227432750
   PubMed Web of Science ®Google Scholar
• Han L, Wang T, Wu J, Yin X, Fang H, Zhang N. A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy. Int J Nanomedicine. 2016;11:6003–6022. doi:10.2147/IJN.S11872727956831
   PubMed Web of Science ®Google Scholar
• Han L, Wang T, Mu S, et al. Unified D-α-Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy. Nanomedicine. 2018;13(11):1285–1301. doi:10.2217/nnm-2017-031629949468
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang J, Hou T, Yin X, Zhang N. Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core–shell nanoparticles for enhanced tumor-localized chemoimmunotherapy. Nanoscale. 2019;11(29):13934–13946. doi:10.1039/c9nr03374b31305839
   PubMed Web of Science ®Google Scholar
• Zhang Z, Cao G, Sha L, Wang D, Liu M. The efficacy of sodium aescinate on cutaneous wound healing in diabetic rats. Inflammation. 2015;38(5):1942–1948. doi:10.1007/s10753-015-0174-525903967
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Q, Li B, et al. Escin-induced DNA damage promotes Escin-induced apoptosis in human colorectal cancer cells via p62 regulation of the ATM/gammaH2AX pathway. Acta Pharmacol Sin. 2018;39(10):1645–1660. doi:10.1038/aps.2017.19229849127
   PubMed Web of Science ®Google Scholar
• Hou H, Li WX, Cui X, Zhou DC, Zhang B, Geng XP. CARMA3/NF-κB signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate. World J Gastroenterol. 2019;25(36):5483–5493. doi:10.3748/wjg.v25.i36.548331576094
   PubMed Web of Science ®Google Scholar
• Cheng CL, Chao WT, Li YH, et al. Escin induces apoptosis in human bladder cancer cells: an in vitro and in vivo study. Eur J Pharmacol. 2018;840:79–88. doi:10.1016/j.ejphar.2018.09.03330287153
   PubMed Web of Science ®Google Scholar
• Berendsen HJC, Van Der Spoel D, Van Drunen R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun. 1995;91(1–3):43–56. doi:10.1016/0010-4655(95)00042-e
   Web of Science ®Google Scholar
• Lindahl E, Hess B, Van Der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model. 2001;7(8):306–317. doi:10.1007/s008940100045
   Web of Science ®Google Scholar
• Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26(16):1701–1718. doi:10.1002/jcc.2029116211538
   PubMed Web of Science ®Google Scholar
• Hess B, Kutzner C, Van Der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4(3):435–447. doi:10.1021/ct700301q26620784
   PubMed Web of Science ®Google Scholar
• Pronk S, Páll S, Schulz R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29(7):845–854. doi:10.1093/bioinformatics/btt05523407358
   PubMed Web of Science ®Google Scholar
• Páll S, Abraham M, Kutzner C, et al. Tackling exascale software challenges in molecular dynamics simulations with gromacs. International Conference on Exascale Applications and Software; 2015:3–27. doi: 10.1007/978-3-319-15976-8_1.
   Google Scholar
• Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25(9):1157–1174. doi:10.1002/jcc.2003515116359
   PubMed Web of Science ®Google Scholar
• Bayly CI, Cieplak P, Cornell W, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem. 1993;97(40):10269–10280. doi:10.1021/j100142a004
   Web of Science ®Google Scholar
• Lu T, Chen F. Multiwfn: a multifunctional wavefunction analyzer. J Comput Chem. 2012;33(5):580–592. doi:10.1002/jcc.2288522162017
   PubMed Web of Science ®Google Scholar
• Adamo C, Barone V. Toward reliable density functional methods without adjustable parameters: the PBE0 model. J Chem Phys. 1999;110(13):6158–6170. doi:10.1063/1.478522
   Web of Science ®Google Scholar
• Marenich AV, Cramer CJ, Truhlar DG. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J Phys Chem B. 2009;113(18):6378–6396. doi:10.1021/jp810292n19366259
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14(1):33–38. doi:10.1016/0263-7855(96)00018-58744570
   PubMedGoogle Scholar
• Hu S, Lee E, Wang C, et al. Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy. J Control Release. 2015;220(Pt A):175–179. doi:10.1016/j.jconrel.2015.10.03126482082
   PubMedGoogle Scholar
• Yin X, Han L, Mu S, et al. Preparation and evaluation of etoposide-loaded lipid-based nanosuspensions for high-dose treatment of lymphoma. Nanomedicine. 2019;14(11):1403–1427. doi:10.2217/nnm-2018-050231180263
   PubMed Web of Science ®Google Scholar
• Zhang H, Hu H, Zhang H, et al. Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis. Nanoscale. 2015;7(24):10790–10800. doi:10.1039/c4nr07450e26038337
   PubMed Web of Science ®Google Scholar
• Li Z, Tian G, Jiang H, et al. Liver-targeting and ph-sensitive sulfated hyaluronic acid mixed micelles for hepatoma therapy. Int J Nanomedicine. 2019;14:9437–9452. doi:10.2147/IJN.S21452831819442
   PubMed Web of Science ®Google Scholar
• Waghray D, Zhang Q. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J Med Chem. 2018;61(12):5108–5121. doi:10.1021/acs.jmedchem.7b0145729251920
   PubMed Web of Science ®Google Scholar
• Li Y, Lin J, Liu G, et al. Dual-acting, function-responsive, and high drug payload nanospheres for combining simplicity and efficacy in both self-targeted multi-drug co-delivery and synergistic anticancer effect. Int J Pharm. 2016;512(1):194–203. doi:10.1016/j.ijpharm.2016.08.03527566011
   PubMedGoogle Scholar
• Lu J, Zhao W, Liu H, et al. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. J Control Release. 2014;196:272–286. doi:10.1016/j.jconrel.2014.10.01625456831
   PubMed Web of Science ®Google Scholar